Depatuxizumab MMAE provides an EGFR-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines the anti-EGFR antibody depatuxizumab with monomethyl auristatin E (MMAE), supporting studies of EGFR-expressing tumors and targeted cytotoxic payload delivery.
Key Features and Benefits
- EGFR-Targeting ADC: Combines an EGFR-directed monoclonal antibody with the cytotoxic MMAE payload.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent specifically used in ADC research.
- EGFR Recognition: Supports research specifically involving EGFR expression, antibody binding, internalization, and tumor-selective targeting.
- Targeted Payload Delivery: Enables investigation of antibody-mediated MMAE delivery to EGFR-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule dynamics, specifically supporting studies of ADC-mediated cytotoxic mechanisms.
- ADC Research Platform: Supports investigation of target engagement, cellular uptake, payload activity, and cellular response.
- Cancer Research: Supports studies involving EGFR-expressing solid tumor models.
Applications
- EGFR-Positive Cancer Research: Supports studies of tumors with elevated or altered EGFR expression.
- ADC Research: Especially useful for investigating antibody targeting, cellular uptake, payload delivery, and cytotoxic activity.
- Targeted Cancer Therapy Research: Supports investigation of antibody-mediated MMAE delivery to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating EGFR-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of EGFR targeting and MMAE-mediated microtubule disruption.
- Solid Tumor Research: Useful for studying EGFR-targeted ADC strategies in relevant solid tumor models.
- Comparative ADC Research: Supports comparison of EGFR-targeted ADC designs, linkers, and auristatin payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from light and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Depatuxizumab MMAE combines EGFR-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports EGFR-positive cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
